Portal de Periódicos da CAPES

Circulating tumor cells in locally advanced pancreatic adenocarcinoma: the ancillary CirCe 07 study to the LAP 07 trial

2013; Elsevier BV; Volume: 24; Issue: 8 Linguagem: Inglês

10.1093/annonc/mdt176

1569-8041

François‐Clément Bidard, F. Huguet, Christophe Louvet, Laurent Mineur, Olivier Bouché, Benoist Chibaudel, Pascal Artru, Françoise Desseigne, Jean‐Baptiste Bachet, Claire Mathiot, Jean‐Yves Pierga, Pascal Hammel,

Cancer Genomics and Diagnostics

Pancreatic carcinoma is one of the leading causes of cancer-related mortality. At the time of diagnosis, 30% of patients present with a locally advanced pancreatic carcinoma (LAPC). As circulating tumor cells (CTCs) count may be a surrogate of the cancer metastatic abilities, CTC detection rates and prognostic value were studied in a prospective cohort of LAPC patients.An LAP07 international multicenter randomized study assesses in patients whose LAPC is controlled after 4 months of chemotherapy whether chemoradiotherapy could increase survival versus continuation of chemotherapy. A subgroup of patients included in the LAP07 trial was screened for CTCs (CellSearch®) before the start of the chemotherapy and after 2 months of treatment. Patient characteristics and survival were obtained prospectively and were correlated with CTC detection.Seventy-nine patients were included. One or more CTCs/7.5 ml were detected in 5% of patients before treatment and in 9% of patients after 2 months of treatment (overall detection rate: 11% of patients). CTC positivity was associated with poor tumor differentiation (P = 0.04), and with shorter overall survival (OS) in multivariable analysis (RR = 2.5, P = 0.01), together with anemia.The evaluation of micrometastatic disease using CTC detection appears as a promising prognostic tool in LAPC patients.